JPRN-UMIN000008314招募中2 期
A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasis - A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasis
Dokkyo Medical University Department of Pulmonary Medicine and Clinivcal Immunology0 个研究点目标入组 40 人开始时间: 2012年7月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Hypersensitivity to denosumab 2) Need of emergency treatment for bone metastasis by radiotherapy or surgery 3) Need of treatment for hypercalcemia 4) Prior use of bisphosphonates 5) Symptomatic brain metastasis 6) Active severe infections 7) Severe odontopathy 8) Interstitial pneumonitis 9) Active concomitant malignancy 10) Pregnant or lactating 11) Uncontrolled heart disease, hepatic disease, diabetes mellitus, bleeding, etc. 12) Problematic psychiatric disease 13) Inappropriate patients for this study judged by the physicians
研究者
相似试验
进行中（未招募）
1 期
A multicenter phase II study evaluating denosumab (XGEVA®) in combination with nivolumab (OPDIVO®) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamous) with bone metastasesEUCTR2018-001105-85-FRCentre Hospitalier Annecy Genevois86
进行中（未招募）
1 期
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869
已完成
不适用
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
已完成
2 期
Denosumab vs Placebo in Patients With Thalassemia Major and OsteoporosisThalassemia MajorOsteoporosisNCT02559648Ersi Voskaridou63
已完成
2 期
Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trialthymic carcinomaJPRN-UMIN000022007ational Cancer Center15